These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16436671)

  • 1. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein.
    Nakamura E; Abreu-e-Lima P; Awakura Y; Inoue T; Kamoto T; Ogawa O; Kotani H; Manabe T; Zhang GJ; Kondo K; Nosé V; Kaelin WG
    Am J Pathol; 2006 Feb; 168(2):574-84. PubMed ID: 16436671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
    Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
    J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC; Cockman ME; Smallwood AC; Mole DR; Woodward ER; Maxwell PH; Ratcliffe PJ; Maher ER
    Hum Mol Genet; 2001 May; 10(10):1029-38. PubMed ID: 11331613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
    Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
    Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF.
    Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG
    Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
    Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
    Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
    Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The VHL tumor suppressor and HIF: insights from genetic studies in mice.
    Kapitsinou PP; Haase VH
    Cell Death Differ; 2008 Apr; 15(4):650-9. PubMed ID: 18219317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of novel VHL target genes and relationship to hypoxic response pathways.
    Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
    Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M
    Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG
    Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Von Hippel-Lindau disease.
    Kaelin WG
    Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
    Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
    BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of VHL gene mutation in human cancer.
    Kim WY; Kaelin WG
    J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
    Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
    Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.